Venture Investors Shift Strategy Toward Refined Modalities, Women’s Health and Platform Discipline

Venture investors and corporate strategists are recalibrating capital deployment toward proven modalities, underfunded disease areas such as fertility and women’s health, and tighter development discipline for platform companies. This strategic shift was a central theme during the BIO-Europe Spring panel Piecing Together the Therapeutic Landscape with Analyst Insights moderated by Daniel Chancellor VP, Thought Leadership Evaluate.

Panellists described a funding environment that increasingly favours validated biology and clearer development pathways earlier in company lifecycles.

The re-emerging strategy signals a move away from speculative platform bets towards targeted technological refinement and disease areas historically overlooked by large pharma, which now sees evolving disease biology as important in portfolio design.

ADCs Enter Refinement Phase Rather Than Reinvention

Among the clearest examples of this strategic shift is the continued investment in antibody-drug conjugates (ADCs), where investors see substantial room for improvement despite the modality’s maturity.

Jan Van den Bossche, partner at Andera Partners, described ADCs as a prime example of innovation through refinement rather than reinvention. “There has been a number of waves already on innovation,” he said. “There is more that we can do to improve the index, to broaden the usage of ADCs in other indications and in tumour types. For instance, the first deal we've done in the new fund is an investment in Adcytherix, a company focused on developing novel payload classes aiming to overcome resistance mechanisms and expanding the reach of ADCs to tumours that respond poorly to this modality.”

His firm has continued backing companies advancing differentiated ADC technologies, reflecting confidence that meaningful improvements remain possible within an established therapeutic class.

Rather than pursuing entirely new mechanisms, it seems investors increasingly favour optimization strategies that reduce risk while maintaining innovation. “I think you don't need to reinvent the wheel. You need to see where the wheel is not round enough and where it can spin faster,” Van den Bossche added.

Fertility and Women’s Health Move into Strategic Focus

While oncology remains dominant, fertility and women’s health were highlighted as areas attracting increasing attention from both venture funds and pharmaceutical companies.

Hakan Goker, managing director at M Ventures, emphasized the firm’s ongoing commitment to fertility and adjacent conditions. “We have been one of the main, let's say, the most active groups in fertility… and we will continue doing… adjacent work around fertility.”

That includes expanding investment into conditions such as endometriosis and adenomyosis, areas historically underserved despite high patient demand.

“These are… diseases… which have still significantly high unmet medical needs, but not many pharma focus on it,” he added.

This increased attention reflects broader recognition that women’s health represents both a clinical and commercial opportunity. M Ventures was the founding investor in fertility and women’s health company ReproNovo, which targets male and female fertility as well as women’s health indications, including adenomyosis. The Lausanne, Switzerland-based company completed a $65 million Series A financing in May 2025.

Industry players have begun treating fertility and related endocrine conditions not as niche markets but as integral components of long-term therapeutic strategies.

Platform Companies Face New Financial Reality

Alongside therapeutic shifts, panellists emphasized tightening expectations for platform-based biotech companies, particularly those seeking early-stage capital.

Investors indicated that broad technology visions without clear development plans are no longer viable in today’s funding climate. “The old days of open-ended… ‘let’s find out what this technology is going to work for’… are gone,” Goker said.

Instead, companies must demonstrate realistic execution pathways and clear milestones early in development.

“You need to have a clear idea… it can still be a rough one, but you need to know where you're going,” he said. Platform technologies, once able to raise capital on broad promises of multi-indication applicability, must now demonstrate practical use cases.

Laura Lane, VP and European head at Lilly Ventures, underscored the importance of early demonstration of functionality. “With platform companies, there needs to be a roadmap with clear examples so people can say, ‘Oh, I see that — it works there,” she said.

Similarly, business development leaders highlighted the importance of defined clinical entry points.

“From a BD perspective, you want to see a good anchor indication,” said Toby Richardson Senior Director, External Scientific Innovation of Johnson & Johnson.

Panelists also noted that evolving disease biology is shaping how companies think about portfolio design.

Sam Bennett, Associate Director, Search & Evaluation of Novo Nordisk said pipeline strategy is increasingly influenced by the convergence of related disease mechanisms. “There has been a paradigm shift over the last five to ten years… from individual disease to a much broader subset of ongoing parallel diseases,” Bennett noted.

Balancing Innovation and Risk

Across therapeutic areas and development strategies, diversification remains a central risk management principle for venture investors.

Van den Bossche emphasized the need to balance innovation with portfolio stability. “For us, the name of the game is to create a diversified portfolio… across therapeutic areas and different modalities,” he said.

The approach is intended to reduce exposure to failure risks inherent in emerging technologies while preserving opportunities for breakthrough innovation.

Even in areas such as ex-vivo cell therapy, at one time among the most aggressively funded modalities, investors have become more cautious. “Ey-vivo cell therapy has not seen a very easy way forward,” Van den Bossche noted.

The caution reflects the growing recognition that capital-intensive therapeutic approaches require clearer commercial viability earlier in development.

Capital Strategy Signals Long-Term Industry Shift

The panelists’ comments indicate a shift that appears structural rather than cyclical. Investors are not retreating from innovation but are becoming more selective about how and where capital is deployed, with clearer expectations around execution, clinical validation and defined development paths.